Aduro biotech, inc. (ADRO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue:
Total revenue

13,950

3,633

4,799

4,888

3,938

2,758

3,063

2,639

6,627

-

3,794

5,917

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration and license revenue

-

-

-

-

-

-

-

-

-

-

-

-

3,772

-

3,794

38,938

3,983

34,108

18,720

9,623

9,238

-

2,424

883

-

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

41

47

268

426

260

336

162

62

102

25

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

3,772

-

3,794

38,979

4,030

34,376

19,146

9,883

9,574

9,893

2,486

985

25

Operating expenses:
Research and development

15,828

17,165

15,510

16,876

17,494

17,613

18,675

19,420

20,128

22,916

24,454

21,440

20,572

20,863

19,046

26,882

20,927

22,657

11,813

13,533

10,646

7,523

5,858

5,403

4,729

General and administrative

7,819

9,908

8,683

7,980

8,224

9,014

9,149

8,827

9,045

8,770

8,458

8,245

8,278

8,022

8,556

8,700

8,999

8,805

6,908

5,882

6,210

3,496

1,980

2,134

1,384

Restructuring and related expense

4,308

-

-

-

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on impairment of intangible assets

-

-

5,006

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

100

177

138

139

100

141

144

147

152

146

145

136

132

134

138

140

137

89

0

0

0

-

-

-

-

Total operating expenses

28,091

24,216

29,337

24,995

28,852

30,760

27,968

28,394

29,325

31,832

33,057

29,821

28,982

29,019

27,740

35,722

30,063

31,551

18,721

19,415

16,856

11,019

7,838

7,537

6,113

Loss from operations

-14,141

-20,583

-24,538

-20,107

-24,914

-28,002

-24,905

-25,755

-22,698

-28,076

-29,263

-23,904

-25,210

-25,141

-23,946

3,257

-26,033

2,825

425

-9,532

-7,282

-1,126

-5,352

-6,552

-6,088

Loss from remeasurement of fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

16,735

9,342

-

157

-25

-

Interest income

920

1,117

1,366

1,497

1,471

1,392

1,353

1,340

1,199

1,016

998

780

650

-

566

-

-

-

-

-

-

-

-

-

-

Interest income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

520

454

-

139

-

-

-

-30

-

-

Gain on extinguishment of convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,553

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

996

1,354

Other expense, net

-19

-39

-32

-3

-19

-49

21

-20

-16

-21

-129

-64

-4

-8

-1

-9

-22

-179

3

7

8

655

855

344

-342

Total other income

901

-

-

-

1,452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income tax

-13,240

-19,505

-23,204

-18,613

-23,462

-26,659

-23,531

-24,435

-21,515

-27,081

-28,394

-23,188

-24,564

-24,470

-23,381

3,768

-25,601

3,001

567

-26,260

-16,616

-

-

-

-

Income tax benefit

-5,700

-90

-2,252

-35

-35

-339

-385

-38

-21

-950

-3,874

-3,788

-2,752

5,096

11,670

1,472

3,226

-99

0

0

0

-

-

-

-

Net loss

-7,575

-19,415

-20,952

-18,578

-23,427

-26,320

-23,146

-24,397

-21,494

-26,131

-24,520

-19,400

-21,812

-29,566

-35,051

2,296

-28,827

3,100

567

-26,260

-16,616

-920

-4,684

-3,626

-7,784

Net loss per common share, basic and diluted

-0.09

-0.25

-0.26

-0.23

-0.29

-0.33

-0.29

-0.31

-0.28

-0.34

-0.33

-0.27

-0.32

-

-0.54

-

-0.45

-

-

-

-39.97

-

-

-12.27

-26.34

Shares used in computing net loss per common share, basic and diluted

80,757

80,504

80,232

80,032

79,673

79,438

79,086

78,817

77,906

77,093

75,167

71,101

68,242

-

65,134

-

63,802

-

-

-

415

-

-

295

295

Net (loss) income per common share, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.04

-

-

0.01

-0.50

-

-

-14.24

-

-

Net (loss) income per common share, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.03

-

-

0.01

-0.50

-

-

-14.24

-

-

Shares used in computing net loss per common share, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64,434

-

-

62,274

52,653

-

-

328

-

-

Shares used in computing net loss per common share, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71,473

-

-

71,726

52,653

-

-

328

-

-

Collaboration and license revenue
Total revenue

13,950

3,633

4,799

4,888

3,938

2,758

3,063

2,639

6,627

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-